National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ? by Aebi-Popp, Karoline et al.
30 Gamble HL, Klosky JL, Parra GR, et al. Factors influencing familial decision-
making regarding human papillomavirus vaccination. J Pediatr Psychol 2010;35:
704–15.
31 Roberts ME, Gerrard M, Reimer R, et al. Mother-daughter communication and
human papillomavirus vaccine uptake by college students. Pediatrics 2010;125:
982–9.
32 Chao C, Velicer C, Slezak JM, et al. Correlates for human papillomavirus
vaccination of adolescent girls and young women in a managed care organization.
Am J Epidemiol 2010;171:357–67.
33 Mills LA, Vanderpool RC, Crosby RA. Sexually related behaviors as predictors
of HPV vaccination among young rural women. J Womens Health 2011;20:1909–15.
34 Cooper Robbins SC, Bernard D, McCaffery K, et al. ‘‘Is cancer contagious?":
Australian adolescent girls and their parents: making the most of limited informa-
tion about HPV and HPV vaccination. Vaccine 2010;28:3398–408.
35 Institut National de Pre´vention et d’Education pour la sante´. Sida: «Avant d’arreˆter
le pre´servatif, faites le test», 2008. Available at: http://www.inpes.sante.fr/70000/dp/
08/dp080617.pdf (15 June 2012, date last accessed).
36 Lo B. HPV vaccine and adolescents’ sexual activity. BMJ 2006;332:1106–7.
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
European Journal of Public Health, Vol. 23, No. 6, 1053–1058
 The Author 2013. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.
doi:10.1093/eurpub/ckt028 Advance Access published on 11 March 2013
. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . .
National Guidelines for the prevention of
mother-to-child transmission of HIV across
Europe – how do countries differ?
Karoline Aebi-Popp1, Fiona Mulcahy1, Christoph Rudin2, Irene Hoesli3, Andrea Gingelmaier4,
Fiona Lyons1, Claire Thorne5
1 St. James’s Hospital, GUIDE Clinic, Dublin, Ireland
2 University Children’s Hospital Basel, Switzerland
3 University Women’s Hospital Basel, Switzerland
4 University Hospital of Munich, Department of Gynaecology and Obstetrics, Munich, Germany
5 MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, University College London, UK
Correspondence: Karoline Aebi-Popp, Department of Genitourinary Medicine and Infectious Diseases (GUIDE), St. James’s
Hospital, Dublin 8, Ireland, tel: (00 353 1) 4162315/2316, fax: (00 353 1) 4103416, e-mail: mail@aebi-popp.com
Objectives: The aim was to summarize national prevention of mother-to-child transmission (PMTCT) guidelines
across Europe and to identify differences between these. Methods: A survey was conducted using a structured
questionnaire sent to experts in 25 European countries from January to March 2012, requesting a copy of the
national guidelines. Responses were received from 23 countries. Results: Twenty-two (96%) countries supported a
policy to recommend antenatal HIV screening for all pregnant women (15: opt-out strategy; 8: opt-in strategy). For
HIV-positive women in whom the only indication for antiretroviral therapy (ART) was PMTCT, the recommended
gestational age for commencing ART varied from 12 to 28 weeks: initiation before 19 weeks gestation was
recommended in guidelines from nine countries; in France, the UK and the Netherlands, there was a wide
range, from 14 to 24 weeks, whereas the Swiss and Ukrainian guidelines recommended starting at 24–28 weeks
and the German/Austrian and Lithuanian at 28 weeks. Six national guidelines recommended inclusion of
Zidovudine in antenatal ART regimens, and seven (37%) allowed continuation of Efavirenz for women
conceiving on this drug. According to nine guidelines, zidovudine should always be used intrapartum. Eighteen
national guidelines stated that HIV-positive women on successful ART can have a vaginal delivery. Viral load
thresholds for vaginal delivery were <1000 copies/ml in 5 countries, <400 copies/ml in 3 and <50 copies/ml in 11
countries. Conclusion: There are important differences across Europe in national PMTCT guidelines, with most
variation seen where the evidence-base remains limited. Such differences should be considered when interpreting
research and surveillance findings.
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Introduction
HIV infection remains of major public health importance inEurope, with a continued increase in the reported diagnosed
HIV cases. According to the UNAIDS (Joint United Nations
Programme on HIV/AIDS) estimates, there were 820 000 people
living with HIV in Western and Central Europe and 1.4 million in
Eastern Europe and Central Asia in 2009, whereas together, the
Russian Federation and Ukraine contribute >80% of all HIV
infections in this region.1 In the European Union and European
Economic Area (EU/EEA), 27 116 new HIV infections were
diagnosed in 2010 and the highest rates of new infections in EU/
EEA were reported by Estonia (27.8), Latvia (12.2), Belgium (11.0)
and the UK (10.7).2
More than one-third of HIV-infected women in Europe are of
childbearing age, but there are relatively limited data on antenatal
HIV prevalence across Europe. In the UK, estimated HIV prevalence
in women delivering is 0.4% in London, 0.1% elsewhere in
England and 0.05% in Scotland,3 whereas this figure was 0.17% in
2009 in Catalonia, Spain4 and 0.7% in St Petersburg, Russia in
2010.5 Advances in prevention of mother-to-child transmission
(PMTCT) of HIV and improved survival and quality of life owing
to antiretroviral therapy (ART) have led to increasing numbers of
women with HIV deciding to have children.6–8 Strategies for
PMTCT are therefore highly important.
The development of clinical guidelines for the management of
pregnant women with HIV and their infants has become an
important and effective tool for implementation of effective
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PMTCT services. Guidelines for PMTCT have been developed at a
national level across most of Europe and are adapted to the
country’s specific needs, and human and economic capacities are
mainly available in the national language.
During the past decade, widespread use of antenatal combination
ART (cART) has been associated with mother-to-child transmission
rates below 1–2% on a population level in many European
countries.9–13 Consequently, most recent European national
guidelines have changed to include the recommendation of vaginal
delivery instead of elective caesarean section (CS) for women with
undetectable or very low HIV viral load (VL) and after exclusion of
other potential risk factors.14,15
Although PMTCT policies have recently been compared between
some countries in Central and Eastern Europe,16 and antenatal HIV
screening policies have been assessed across Europe several times
during recent years,17–19 to date there has been no attempt to
contrast and compare national PMTCT policies across Europe as a
whole. The aim of this study was to ascertain and summarize
national PMTCT guidelines across Europe, with a main focus on
temporal and geographical patterns of antenatal ART and mode of
delivery and to identify international variability. This should
facilitate the interpretation of research findings from different
countries and the identification of areas with limited evidence.
Methods
We conducted a survey between January and March 2012 using a
short structured questionnaire sent by email with a letter, requesting
collaboration, to experts (mainly infectious diseases specialists or
obstetricians at university hospitals) in 25 European countries,
chosen to represent all European regions (as defined by United
Nations) and with those countries with the greatest HIV burden
included. Those experts were identified through established clinical
HIV networks: PENTA (Paediatric European Network for
Treatment of AIDS) and EPPICC (European Pregnancy and
Paediatric HIV Cohort Collaboration in EuroCoord) and SHE
(Network of Strong, HIV positive, Empowered women, www.
shetoshe.org). Additionally, we asked for a copy of the national
guidelines to validate the survey responses. Those were reviewed in
terms of the correlation to the expert’s answers. The questionnaire
was designed to obtain descriptive information about national
policies regarding pregnancy and mode of delivery in HIV-infected
women.
The survey included specific questions on the following issues:
antenatal HIV testing strategies, recommended timing of ART
initiation during pregnancy for women only requiring this for
PMTCT, substitution of Efavirenz if treatment containing this
drug was on-going at conception and during pregnancy, vaginal
delivery in HIV-infected women and the applicable HIV
ribonucleicacid threshold, recommended mode of delivery with
hepatitis C virus (HCV) co-infection, option of Zidovudine
(ZDV) monotherapy during pregnancy, use of intrapartum ZDV
and duration and composition of infant prophylaxis. Experts who
did not respond within one month were reminded by email.
Following non-response after a reminder, an alternative expert
from that country was contacted in two cases.
We obtained answers from 23 of 25 countries with a response rate
of 92%. Survey responses were available for the following 23
countries: Belgium, Denmark, Estonia, Finland, France, Germany/
Austria (conjoint guidelines), Greece, Hungary, Ireland, Italy,
Lithuania, Moldova, Norway, Poland, Portugal, Russia, Slovakia,
Spain, Sweden, Switzerland, The Netherlands, UK and Ukraine.
No response was received from contacted experts from Bulgaria or
Romania. Of the 23 countries for which questionnaires were
returned, 19 had national written guidelines, published between
2007 and 2011. No official country-specific guidelines existed in
Belgium, Estonia, Finland and Slovakia (confirmed by the
appropriate national experts). As antenatal HIV testing policies are
a component of national antenatal care policies (i.e. not HIV-
specific), we present results on policies for HIV testing in
pregnancy for all 23 countries. All other results are restricted to
the 19 countries with national written guidelines.
Results
Testing strategies for HIV during pregnancy
In all but one (22 of the 23) countries, there was a policy to
recommend antenatal HIV screening for all pregnant women; the
exception was in ‘Hungary’, where testing was performed only if
requested by the mother. Of the 22 countries with universal recom-
mendation of HIV testing in pregnancy, in the majority (n= 16,
73%), there was an opt-out screening strategy (table 1); under this
approach, pregnant women are told that a HIV test will be included
in the standard routine prenatal tests and that they may decline the
test. Unless they decline, they will undergo HIV testing. In the
remaining seven (32%) countries, there was an opt-in policy,
whereby HIV testing is offered by the physician or other health
care professional and can only be carried out with specific
informed consent from the woman. In Russia, pregnant women
are in general asked to sign an informed consent for HIV testing
during pregnancy. The year when the current national recommen-
dations for antenatal HIV screening were adopted are shown in
table 1 where available and varied between 1987 in Sweden and
Norway to 2010 in Denmark, where a universal opt-out strategy
was introduced following a previous policy of selective screening
(i.e. of specified risk groups).
Start of ART during pregnancy in women not
requiring treatment for their own health
Use of antiretroviral treatment or prophylaxis during the antenatal
period was recommended for all HIV-infected pregnant women,
regardless of plasma HIV ribonucleicacid level or CD4 cell counts
in all national guidelines reviewed (n= 19). The recommended ges-
tational age for commencing ART during pregnancy varied between
12 and 28 weeks of gestation for HIV-infected women in whom the
only indication for ART was PMTCT (table 2). In nine (47%) of the
countries surveyed, there was a policy to advise initiation of prophy-
lactic ART at circa 14 weeks of gestation. Although the German/
Austrian guidelines had the recommendation to routinely start
prophylaxis at 28 weeks of pregnancy, they did advise an earlier
Table 1 HIV-testing strategies recommended for pregnant women
in 22 countries with policy of universal recommendation for
antenatal HIV testing (years when national recommendations were
adopted)
Opt-in strategy Opt-out strategy
France (1992) Belgium
Germany/Austria (1989) Denmark (2010)
Greece (1996) Estonia (1991)
Moldova (2004) Finland (1998)
Poland Italy (2001)
Russia Ireland (1999)
Lithuania (2002)
Norway (1987)
Portugal (1996)
Slovakia (1991)
Spain (1995)
Sweden (1987)
Switzerland (2003)
The Netherlands (2004)
UK (England 2000)
Ukraine
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start (24 gestational weeks) in cases of high maternal HIV VL or risk
factors for preterm delivery.
Use of ZDV and Efavirenz
In the majority (n= 14, 74%) of countries surveyed, there was not an
explicit recommendation that ZDV should be included in all
antenatal ART regimens for women in receipt of combined ART.
However, this was the case in five (26%) countries (table 3). In eight
(42%) countries, there was a recommendation for intrapartum use
of oral (if not available intravenously) or intravenous ZDV for all
HIV-positive women (table 3). ZDV monotherapy coupled with an
elective CS was considered to be an appropriate management option
for a selected group of women with low VL in three countries (UK
below 10 000 c/ml, Lithuania below 1000 c/ml, Ireland undetectable;
table 3). In 13 (68%) countries, it was recommended that
Efavirenz-containing regimens should be avoided in women who
are planning a pregnancy, and that women on such regimens at
conception should be switched to a different drug (table 3).
Vaginal delivery in HIV-infected women
In most (n= 18, 95%) countries surveyed, national guidelines
included the recommendation that HIV-positive women on
successful cART with a very low or undetectable VL can have a
vaginal delivery. Countries incorporated this recommendation into
their national guidelines at different times (table 4). Experts reported
that practice changes proceeding policy change were common
regarding vaginal deliveries. In Greece, the national guidelines
continue to recommend elective CS as the preferred mode of
delivery in HIV-infected women without mentioning the option of
vaginal delivery.
Maternal VL at 36 weeks of pregnancy was an important factor
when deciding on mode of delivery in most (12, 63%) countries,
whereas experts of the Netherlands suggest that women without an
undetectable HIV VL at 36 weeks can still be considered for a vaginal
delivery if they achieve an undetectable VL at term. In Moldova, the
decision about mode of delivery is made on the basis of VL meas-
urement at 38 weeks of gestation. In contrast, the Swiss guidelines
recommend having an undetectable HIV VL for three consecutive
measurements before delivery, whereas the Italian guidelines
recommend that decision making regarding mode of delivery is
made between 30 and 34 weeks of gestation. The Lithuanian
guidelines suggest that vaginal delivery should be available on
maternal request, if the VL was undetectable during several meas-
urements for 4–6 weeks before the estimated date of delivery. Danish
guidelines showed that elective CS is the preferred mode of delivery
in any HIV-infected women, but the mother can opt for vaginal
delivery if the VL is below 1000 copies/ml at 36 weeks of
pregnancy. In Russia, the national policy is to perform an elective
CS if the VL at 38 weeks is above 1000 copies/ml. There are
countries, where the guidelines would allow vaginal delivery under
certain circumstances if requested by the mother (e.g. Denmark,
Lithuania and Poland), whereas elsewhere, the national guidelines
encourage women to favour vaginal delivery under optimal
circumstances.
In case of HIV/HCV co-infection, elective CS was recommended
as the most appropriate mode of delivery in 10 (53%) countries
(France, Greece, Hungary Ireland, Italy, Lithuania, Moldova,
Norway, Sweden and Switzerland). In the remaining nine
countries, the guidelines specified the option of vaginal delivery in
Table 3 Recommendations regarding use of ZDV and Efavirenz
ZDV Antenatal cART should contain ZDV Greece, Hungary, Lithuania, Russia, Spain, Ukraine
Intrapartum use for all women Greece, Italy, Lithuania, Moldova, Portugal, Russia, Spain, Ukraine
Intrapartum use only for specific scenarios Denmark, France, Germany/Austria, Hungary, Ireland, Norway,
Poland, Sweden, Switzerland, The Netherlands, UK
ZDV monotherapy plus elective
CS for selected groups
Ireland, Lithuania, UK
Efavirenz Stop Efavirenz if pregnant Denmark, France, Germany/Austria, Greece, Hungary, Italy,
Lithuania, Poland, Portugal (if <10 weeks), Russia, Spain,
Switzerland, Ukraine
Continue Efavirenz if virologically stable Ireland, Moldova, Norway, Portugal (if >10 weeks), Sweden, UK,
The Netherlands
Table 4 Year of published guidelines including recommendation for vaginal delivery in HIV infected women with suppressed VL. Table does
not include Belgium, Estonia, Finland and Slovakia (no written guidelines) and does not include Greece (recommend CS) and Russia [vaginal
delivery (VD) if VL< 1000 c/ml]
1999 2001 2002 2004 2007 2008 2009 2010
The Netherlands Ireland France Moldova Denmark Germany/Austria Hungary Italy
Lithuania Poland Norway Sweden
Spain UK Portugal
Ukraine Switzerland
Table 2 Recommended timing of ART start during pregnancy in
women without indication for therapy for their own health
Gestational weeks
12–14
weeks
14–18 weeks 20–24 weeks 24–28 weeks 28 weeks
Italy Sweden Ireland Switzerland Germany/Austria
Poland Norway Moldova (22–24) Ukraine Lithuania
Portugal Denmark
Greece Spain
Russia (16–18)
Hungary (16–18)
14–24 weeks
France
UK
The Netherlands
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HIV/HCV co-infected women, if HIV VL was completely
suppressed.
Infant prophylaxis
ZDV monotherapy as a suspension two to four times daily for 4–6
weeks for the infant was the recommended prophylaxis in most
situations (14 of the 19 countries, 74%). In countries with capacity
to do those analyses ZDV monotherapy was advised provided that
supressed maternal VL and no resistance to ZDV was shown.
Guidelines of Moldova and Ukraine advised 1 week ZDV prophylaxis.
Of note, in the remaining countries, most (n= 12, 63%) national
guidelines recommended shorter durations of 4 weeks. In the
Netherlands, the recommendation was for 4 weeks of neonatal
prophylaxis with dual therapy [ZDV and 3TC (Lamivudine)].
Discussion
Written national guidelines for the management of HIV-infected
pregnant women and their infants existed in 19 of the 23
European countries participating in our survey. Although these
guidelines largely agreed on general management of pregnant
women, they differed in some important aspects. Reasons for this
are likely to be multiple, but a major explanation is the lack of
randomized clinical trial (RCT) data to answer specific
management questions in HIV-positive pregnant women resulting
in a reliance on observational data and expert opinion for some
management issues. In some cases, there is RCT evidence, but this
may be ‘historic’ and less relevant for the contemporary population
of HIV-positive pregnant women in Europe, of whom >90% use
cART.10
Identification of HIV-positive pregnant women is the critical
entry point to PMTCT services, as reflected in universal antenatal
HIV testing policies throughout Europe, which is a cost-effective
strategy.20–22 Opt-out strategies, adopted by most countries here,
have led to remarkable increases in antenatal testing rates 23,24 and
have the added benefit of encouraging ‘normalisation’ of HIV testing
in the general population and reducing stigma associated with
testing. However, it is important that pregnant women are aware
of the system in place and how to opt out, to avoid involuntary
testing.25 Increasing proportions of pregnant women with HIV are
already aware of their status before conception, in many cases
following antenatal diagnosis in a previous pregnancy.26 Not all
diagnosed women will be on ART at conception, and recent
studies have demonstrated some concerning findings regarding
this group of women, including an increased risk of late initiation
of antenatal ART, possibly reflecting disengagement from HIV care
after their earlier pregnancy.27,28
In 2009, rapid advice from the World Health Organization (later
incorporated into the 2010 World Health Organization guidelines for
use of antiretroviral drugs in pregnancy) recommended that prophy-
laxis should start as soon as possible in the second trimester in women
only needing antiretroviral drugs for PMTCT.29 Although there was
no RCT evidence behind this advice, the expert group determined
that the body of observational evidence was sufficient to make this
recommendation. The current US Department of Health and Human
Services (DHHS) guidelines suggest starting antiretroviral prophy-
laxis at 10–12 weeks of pregnancy, regardless of maternal VL,
reflecting findings that early control of HIV replication in
pregnancy is associated with decreased transmission in women with
undetectable VL at delivery.30 However, the European AIDS Society
recommends start of prophylaxis at 28 weeks in women without
treatment indication, or earlier with high VL,31 which is considerably
later than most national guidelines evaluated here, with the majority
recommending start before 24 weeks.
With respect to type of antenatal ART for PMTCT, cART pre-
dominates across Europe, with few women in Western Europe now
receiving ZDV monotherapy9 and only three national policies
including recommendation for ZDV monotherapy in specific
situations. In Ukraine, a lower-middle income setting, although
national policy has recommended cART for PMTCT since 2007,
40% of HIV-positive women delivering in 2010 received ZDV
monotherapy, most likely reflecting limited availability of cART.32
Such findings underscore the need to take into account factors such
as health economics, as well as epidemiology; for example, the
number of pregnancies in HIV-positive women per year ranges
from 5000 in Ukraine, to 1500 in the UK, to <20 in Hungary.
Our finding regarding use of Efavirenz in pregnancy most likely
reflects the fact that some experts remain concerned about the pos-
sibility of birth defects33,34 associated with Efavirenz exposure,
despite the Antiretroviral Pregnancy Registry having identified no
increased risk.35 The very low mother-to-child transmission rates in
women on cART with very low or undetectable VL, irrespective of
mode of delivery,9,14,36,37 led to modification of mode of delivery
policies in Europe, which previously recommended delivery by
elective CS. A European study demonstrated national differences
in mode of delivery practices (based on data up to 2007), for
example, with higher elective CS rates in Italy and Spain than in
Northern Europe in the cART era.14 By the time of this survey in
2012, we found almost complete consensus on the recommendation
of planned vaginal delivery for women on cART with low or un-
detectable VL; as expected, given the findings by the European
Collaborative Study, a prospective cohort study of pregnant
women with HIV, there was a wide time variation by country in
the year of recommendation. Of note, a European pooled analysis
and a single centre Spanish study both highlighted that obstetric
practice does not always follow policy, with some women eligible
for vaginal delivery undergoing CS.15,38 Furthermore, in the
HIV-infected pregnant population in Europe, there are missed
opportunities to achieve full suppressed VL at time of
delivery,10,28,36 and therefore to deliver vaginally.
Although we show widespread use of ZDV monotherapy for
neonatal prophylaxis in most situations, use of combination
neonatal prophylaxis in situations where the infant is perceived to
be at high risk of infection is increasing across Europe; in a recent
pooled analysis of >5000 high risk mother–infant pairs, a quarter of
neonates received combination prophylaxis.39
Our analysis of PMTCT policy approaches across Europe was
cross-sectional, and it is important to consider that some guidelines
have been updated more recently than others, with the oldest last
updated 4–5 years ago. Clinical guidelines should reflect up-to-date
knowledge, and most guidelines are therefore regularly updated.40,41
The constantly expanding evidence base on HIV, pregnancy and
PMTCT and the considerable time and effort needed to update
guidelines explains the time interval between updated versions
(e.g. British, 2008 and 2012; Spanish, 2007 and 2012; German, 2008
and 2011; Switzerland, 2004 and 2009). Thus, some examples
of varying recommendations across countries may partly reflect
the relative timing of the publication of new evidence versus
the year of publishing the guidelines. Other factors behind differ-
ences in clinical guidelines may include different methods of
evaluating the literature and the subsequent interpretation of this
evidence.
This survey is limited by its cross-sectional nature, and interpret-
ation needs to take account of the fact that we have described
policies and not practices. We did not examine implementation of
guidelines or different practices between or within countries.
Furthermore, we restricted our synthesis of policies to those
countries with a written national policy.
Conclusion
This is the first study comparing guideline recommendations for
PMTCT across Europe. These findings are of interest to identify
discordance in guidelines indicating areas where more research is
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needed and to substantiate the difficulties in pooling data from
different countries for research. At the same time, an understanding
of different policies across countries facilitates interpretation of
clinical and epidemiological studies. In the context of uncertainty
regarding effectiveness of specific interventions, clinical heterogen-
eity may allow comparison of different management approaches in
future research. This report could form the basis for discussion
across Europe to share experience and expertise and to identify
future research opportunities to provide the best care for
HIV-infected pregnant women.
Acknowledgements
The authors wish to thank the following for completing the question-
naire: Dr. Inka Aho (University Central Hospital, Helsinki, Finland),
Dr. Elie Azria (Groupe hospitalier Bichat Claude Bernard, Paris
France), Dr. Denes Banhegyi (Saint Laszlo Hospital, Budapest,
Hungary), Dr. Bente Magny Bergersen (Oslo University Hospital,
Norway), Prof. assistant Kees Boer (Academic Medical Centre,
Amsterdam, The Netherlands), Dr. Teresa Branco (Hospital
Fernando Fonseca, Lisbon, Portugal), Dr. Ala Curteanu
(Mother&Child Health Protection Research Institute, Chisinau,
Republic of Moldova), Dr. Ilse Kint (HIV clinic, Institute of
Tropical Medicine, Antwerp, Belgium), Prof. M.D. Evgeny Voronin
and Dr. Inga Latysheva (Republican Clinical Hospital of Infectious
Diseases, St.Petersburg, Russia), Dr. Marta Lo´pez (Hospital Clinic,
Barcelona, Spain), Dr. Magdalena Marczynska (Medical University/
Infectious Diseases Hospital, Warsaw, Poland), Prof. Meile
Minkauskiene (University of Health Sciences, Lithuania), Dr. Lars
Nave´r (Karolinska University Hospital. Stockholm, Sweden), Dr.
Ton Noguera (Hospital Sant Joan de De´u, University of Barcelona,
Barcelona, Spain), Dr. Zlatica Ondrusova´, (Faculty hospital, Trnava,
Slovakia), Dr. Marina Ravizza and Prof. Antonella d’Arminio
Monforte (San Paolo University Hospital, Milan Italy), Dr. Pablo
Rojo Conejo (Hospital 12 de Octubre, Madrid, Spain), Dr. Igor
Semenenko (Perinatal Prevention of AIDS Initiative, Odessa,
Ukraine), Dr. Vana Spoulou (University School of Medicine,
Athens, Greece), Dr. Nina Weis (University Hospital, Copenhagen,
Denmark), Dr. Kai Zilmer (West-Tallinn Central Hospital Estonia).
They also thank Prof. Carlo Gianquinto for his support to facilitate
the contact to national experts for PMTCT.
K.A., F.M. and C.T. contributed to study concept and to study
design. K.A., I.H. and C.T. were involved in the acquisition of data.
K.A. and C.T. drafted the manuscript. All authors critically revised
the manuscript for important intellectual content and read and
approved the final manuscript.
Funding
K.A. was supported by a fellowship research grant of the University
Hospital in Basel, Switzerland while working at St. James’s Hospital
in Dublin, Ireland.
Conflicts of interest: None declared.
Key points
 This is the first study to synthesize PMTCT guidelines across
a broad range of European countries.
 Results contribute to interpretation of research and surveil-
lance data of different countries.
 These results highlight the areas of management of HIV-
positive women where the evidence base remains incomplete.
 PMTCT policy differences between countries relate to their
specific context, in terms of epidemiology of HIV and their
health care systems.
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Background: The Eastern border of the European Union (EU) consists of 10 countries after the expansion of the EU
in 2004 and 2007. These 10 countries border to the East to countries with high tuberculosis (TB) notification rates.
We analyzed the notification data of Europe to quantify the impact of cross-border TB at the Eastern border of the
EU. Methods: We used TB surveillance data of 2010 submitted by 53 European Region countries to the European
Centre for Disease Prevention and Control and the World Health Organization Regional Office for Europe.
Notified TB cases were stratified by origin of the case (national/foreign). We calculated the contribution of
foreign to overall TB notification. Results: In the 10 EU countries located at the EU Eastern border, 618 notified
TB cases (1.7% of all notified TB cases) were of foreign origin. Of those 618 TB cases, 173 (28.0%) were from
countries bordering the EU to the East. More specifically, 90 (52.0%) were from Russia, 33 (19.1%) from Belarus, 33
(19.1%) from Ukraine, 13 (7.5%) from Moldova and 4 (2.3%) from Turkey. Conclusions: Currently, migrants
contribute little to TB notifications in the 10 EU countries at the Eastern border of the EU, but changes in
migration patterns may result in an increasing contribution. Therefore, EU countries at the Eastern border of
the EU should strive to provide prompt diagnostic services and adequate treatment to migrants.
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Introduction
In 11 European Union and European Economic Area (EU/EEA)countries, >50% of the notified tuberculosis (TB) cases are
diagnosed in individuals of foreign origin.1 In 2010, 21% of the
notified multidrug-resistant tuberculosis (MDR-TB) cases in the
EU countries were diagnosed in individuals of foreign origin.1 The
number of notified TB cases in Norway and Sweden was 339 and
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